Teva Pharmaceutical Industries (TEVA) Non Operating Income (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non Operating Income for 18 consecutive years, with -$216.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non Operating Income rose 4.0% year-over-year to -$216.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$925.0 million (up 3.24% YoY) and the FY2025 annual result came in at -$934.0 million, up 4.79% from the prior year.
• Non Operating Income advanced to -$216.0 million in Q1 2026 per TEVA's latest filing, from -$220.0 million in the prior quarter.
• Over the last five years, Non Operating Income for TEVA reached as high as -$211.0 million in Q2 2022 and fell as low as -$280.0 million in Q3 2023.
• A 5-year average of -$244.4 million and a median of -$249.0 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income gained 22.99% — and 2023, when it dropped 27.01%.
• Year by year, Non Operating Income stood at -$245.0 million in 2022, then slipped by 1.63% to -$249.0 million in 2023, then advanced by 12.45% to -$218.0 million in 2024, then slipped by 0.92% to -$220.0 million in 2025, then advanced by 1.82% to -$216.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$216.0 million, -$220.0 million, and -$237.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.